当前位置：
X-MOL 学术
›
Br. J. Cancer
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Prognostic and clinical impact of PD-L2 and PD-L1 expression in a cohort of 437 oesophageal cancers.
British Journal of Cancer ( IF 6.4 ) Pub Date : 2020-03-25 , DOI: 10.1038/s41416-020-0811-0 Kazuo Okadome 1 , Yoshifumi Baba 1, 2 , Daichi Nomoto 1 , Taisuke Yagi 1 , Rebecca Kalikawe 1 , Kazuto Harada 1 , Yukiharu Hiyoshi 1 , Yohei Nagai 1 , Takatsugu Ishimoto 1 , Masaaki Iwatsuki 1 , Shiro Iwagami 1 , Yuji Miyamoto 1 , Naoya Yoshida 1 , Masayuki Watanabe 3 , Yoshihiro Komohara 4 , Takashi Shono 5 , Yutaka Sasaki 5 , Hideo Baba 1
British Journal of Cancer ( IF 6.4 ) Pub Date : 2020-03-25 , DOI: 10.1038/s41416-020-0811-0 Kazuo Okadome 1 , Yoshifumi Baba 1, 2 , Daichi Nomoto 1 , Taisuke Yagi 1 , Rebecca Kalikawe 1 , Kazuto Harada 1 , Yukiharu Hiyoshi 1 , Yohei Nagai 1 , Takatsugu Ishimoto 1 , Masaaki Iwatsuki 1 , Shiro Iwagami 1 , Yuji Miyamoto 1 , Naoya Yoshida 1 , Masayuki Watanabe 3 , Yoshihiro Komohara 4 , Takashi Shono 5 , Yutaka Sasaki 5 , Hideo Baba 1
Affiliation
|
BACKGROUND
The PD-1/PD-L1 pathway plays critical roles in tumour immunology, and serves as an immune-based therapeutic target. Less is known regarding PD-L2, another ligand of PD-1, and its relation to clinical outcome in human cancers.
METHODS
We used a database of 437 surgically and 100 endoscopically resected oesophageal cancers (squamous cell carcinoma, n = 483; adenocarcinoma, n = 36; others, n = 18) to evaluate PD-L2 and PD-L1 expression by immunohistochemistry.
RESULTS
Compared with PD-L2-negative cases (n = 366, 83.8%), PD-L2-positive cases (n = 71, 16.2%) had worse overall survival (P = 0.011, log-rank test). There was not a significant correlation between PD-L2 and PD-L1 expression. Multiplex immunofluorescence revealed that there was variability in the expression pattern of PD-L2 and PD-L1. In early-stage tumours, PD-L2 expression was more frequently observed compared with PD-L1.
CONCLUSIONS
PD-L2 as well as PD-L1 were associated with an unfavourable prognosis in oesophageal cancer, supporting the role of PD-L2 as a prognostic biomarker. Considering that PD-L2 and PD-L1 had different features in terms of expression timing and responses to chemotherapeutic drugs, evaluation of both PD-L2 and PD-L1 expression may be clinically important.
中文翻译：
PD-L2 和 PD-L1 表达对 437 例食管癌队列的预后和临床影响。
背景PD-1/PD-L1通路在肿瘤免疫学中发挥着关键作用，并作为基于免疫的治疗靶点。关于 PD-L2（PD-1 的另一种配体）及其与人类癌症临床结果的关系知之甚少。方法 我们使用包含 437 例手术切除食管癌和 100 例内镜切除食管癌（鳞状细胞癌，n = 483；腺癌，n = 36；其他，n = 18）的数据库，通过免疫组织化学评估 PD-L2 和 PD-L1 表达。结果 与 PD-L2 阴性病例 (n = 366, 83.8%) 相比，PD-L2 阳性病例 (n = 71, 16.2%) 的总生存率较差 (P = 0.011, 对数秩检验)。PD-L2 和 PD-L1 表达之间不存在显着相关性。多重免疫荧光显示 PD-L2 和 PD-L1 的表达模式存在差异。在早期肿瘤中，与 PD-L1 相比，PD-L2 表达更常见。结论 PD-L2 和 PD-L1 与食管癌的不良预后相关，支持 PD-L2 作为预后生物标志物的作用。考虑到PD-L2和PD-L1在表达时间和对化疗药物的反应方面具有不同的特征，因此对PD-L2和PD-L1表达的评估可能具有临床重要意义。
更新日期：2020-04-24
中文翻译：
PD-L2 和 PD-L1 表达对 437 例食管癌队列的预后和临床影响。
背景PD-1/PD-L1通路在肿瘤免疫学中发挥着关键作用，并作为基于免疫的治疗靶点。关于 PD-L2（PD-1 的另一种配体）及其与人类癌症临床结果的关系知之甚少。方法 我们使用包含 437 例手术切除食管癌和 100 例内镜切除食管癌（鳞状细胞癌，n = 483；腺癌，n = 36；其他，n = 18）的数据库，通过免疫组织化学评估 PD-L2 和 PD-L1 表达。结果 与 PD-L2 阴性病例 (n = 366, 83.8%) 相比，PD-L2 阳性病例 (n = 71, 16.2%) 的总生存率较差 (P = 0.011, 对数秩检验)。PD-L2 和 PD-L1 表达之间不存在显着相关性。多重免疫荧光显示 PD-L2 和 PD-L1 的表达模式存在差异。在早期肿瘤中，与 PD-L1 相比，PD-L2 表达更常见。结论 PD-L2 和 PD-L1 与食管癌的不良预后相关，支持 PD-L2 作为预后生物标志物的作用。考虑到PD-L2和PD-L1在表达时间和对化疗药物的反应方面具有不同的特征，因此对PD-L2和PD-L1表达的评估可能具有临床重要意义。
京公网安备 11010802027423号